MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/tid.70150

Медицинская библиотека · Transplant infectious disease : an official journal of the Transplantation Society · 2025

Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates.

Pama-Ghuman Ajmeet K, Sood Puneet, Fung Monica, Roll Garrett R, Mello Anna, Kumar Lakshin, Limaye Ajit P

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Recipient cytomegalovirus (CMV) serostatus reassessment proximate to transplant for initially CMV seronegative patients is critical to guide post-transplant CMV preventive strategies in kidney transplant recipients (KTR), since seroconversion during the long wait-list time could lead to CMV serostatus misclassification. The feasibility and optimal timing of CMV serostatus reassessment and the incidence of seroconversion have not been systematically examined.

METHODS

Program adherence to a guideline for CMV serology reassessment within 6 months of transplant among initially CMV seronegative adults undergoing a first kidney transplant between December 17, 2022 and December 17, 2024 was retrospectively assessed. The association of baseline and transplant factors with adherence was compared by chi-square or Fisher's exact test (p < 0.05 considered significant). The incidence of CMV seroconversion between the time of listing and transplant was calculated per person-years of follow-up.

RESULTS

Among 823 adult KTR, 586 (71.2%) were eligible and 127 (21.7%) were CMV seronegative at listing. The median (interquartile range) time to transplant was longer for deceased (5.23 [2.86-7.44] years) than living donor KTR (1.51 [0.76-2.74] years). Program adherence was 91.3% (116/127) overall and higher among living (65/65 [100%]) versus deceased donor transplants (51/62 [82.3%]), p < 0.01). No demographic or transplant-related variables were associated with adherence (p > 0.05 for all variables). Seroconversion between listing and transplant occurred in two of 124 patients (1.6%), an incidence of 0.0043 per person-year of follow-up.

CONCLUSION

Program adherence to CMV serostatus reassessment within 6 months of transplant was high in a clinical setting and identified a low incidence of seroconversion.

Для цитирования: Pama-Ghuman Ajmeet K, Sood Puneet, Fung Monica, Roll Garrett R, Mello Anna, Kumar Lakshin, Limaye Ajit P. Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates.. Transplant infectious disease : an official journal of the Transplantation Society. 2025. DOI: 10.1111/tid.70150.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.